Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

*Catriona A. Hayes, MD, *Paul Dowling, PhD, Joseph Negri, Michael Henry, Leutz Buon, Jana Jakubikova, PhD, Jake E Delmore, Douglas W. McMillin, PhD, Steffen Klippel, PhD, Hannah M. Jacobs, Niels W.C.J. van de Donk, MD, PhD, Eugen Dhimolea, PhD, Panisinee Lawasut, MD, MSc, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Martin Clynes, PhD, *Peter O Gorman, MD, PhD, *Constantine S. Mitsiades, MD, PhD

Blood (2011) 118 (21): 1820.

https://doi.org/10.1182/blood.V118.21.1820.1820

Published: 2011

Journal Articles

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Niels W.C.J. van de Donk, MD, PhD, Henk M. Lokhorst, MD, Maarten Emmelot, Tineke Aarts-Riemens, Douglas W. McMillin, PhD, Gullu Gorgun, PhD, Steffen Klippel, PhD, Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Jake E Delmore, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1838.

https://doi.org/10.1182/blood.V118.21.1838.1838

Published: 2011

Journal Articles

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Jana Jakubikova, Sophia Adamia, Maria Kost-Alimova, Steffen Klippel, David Cervi, John F. Daley, Dana Cholujova, Sun-Young Kong, Merav Leiba, Simona Blotta, Melissa Ooi, Jake Delmore, Jacob Laubach, Paul G. Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2011) 117 (17): 4409–4419.

https://doi.org/10.1182/blood-2010-02-267344

Published: 2011

Includes: Supplemental data

Journal Articles

Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions.

Efstathios Kastritis, Jana Jakubikova, Jake Delmore, Steffen Klippel, Douglas W. McMillin, Melissa Ooi, Hannah M. Jacobs, Jacob P. Laubach, Paul G Richardson, Kenneth C. Anderson, Andrew L. Kung, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 1574.

https://doi.org/10.1182/blood.V116.21.1574.1574

Published: 2010

Journal Articles

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Jana Jakubikova, PhD, Steffen Klippel, PhD, Efstathios Kastritis, MD, John Daley, Melissa Ooi, MD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 1581.

https://doi.org/10.1182/blood.V116.21.1581.1581

Published: 2010

Journal Articles

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Jana Jakubikova, PhD, Melissa Ooi, MD, Steffen Klippel, PhD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 5016.

https://doi.org/10.1182/blood.V116.21.5016.5016

Published: 2010

Journal Articles

Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.

Douglas McMillin, Jake Delmore, Ellen Weisberg, Joseph M. Negri, Steffen Klippel, Nicholas Mitsiades, Nikhil C. Munshi, James D Griffin, Paul G. Richardson, Kenneth C. Anderson, Andrew L. Kung, Constantine S. Mitsiades

Blood (2009) 114 (22): 1722.

https://doi.org/10.1182/blood.V114.22.1722.1722

Published: 2009

Journal Articles

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Melissa G Ooi, M.D., Robert O'Connor, Ph.D, Jana Jakubikova, Ph.D, Justine Meiller, Diploma, in, Biochemistry, Degre, Steffen Klippel, Ph.D, Jake Delmore, Efstathios Kastritis, M.D, Douglas McMillin, Ph.D, Martin Clynes, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Peter O'Gorman, M.D., Kenneth C. Anderson, M.D.

Blood (2009) 114 (22): 1729.

https://doi.org/10.1182/blood.V114.22.1729.1729

Published: 2009

Journal Articles

Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.

Steffen Klippel, Jana Jakubikova, Jake Delmore, Melissa G. Ooi, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2009) 114 (22): 1741.

https://doi.org/10.1182/blood.V114.22.1741.1741

Published: 2009

Journal Articles

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Jake Delmore, David N. Cervi, Douglas McMillin, Efstathios Kastritis, Jana Jakubikova, Melissa G. Ooi, Steffen Klippel, Joseph M. Negri, Leutz Buon, Jacob Laubach, Luca Rastelli, Ann Clark, Samantha M. Sarno, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 730.

https://doi.org/10.1182/blood.V114.22.730.730

Published: 2009

Journal Articles

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Jana Jakubikova, David N. Cervi, John F. Daley, Danka Cholujova, Melissa G. Ooi, Steffen Klippel, Simona Blotta, Merav Leiba, Jake Delmore, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 954.

https://doi.org/10.1182/blood.V114.22.954.954

Published: 2009

Journal Articles

Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro , and Inhibits Tumor Growth and Improves Survival in in Vivo M ultiple Myeloma(MM) Animal Models

Merav Leiba, MD, Jana Jakubikova, Steffen Klippel, Constantine S. Mitsiades, MD, PhD, Teru Hideshima, Yu-Tzu Tai, Paul Richardson, Yutaka Okawa, Hiroshi Ikeda, Arnon Nagler, Kenneth C. Anderson

Blood (2008) 112 (11): 2754.

https://doi.org/10.1182/blood.V112.11.2754.2754

Published: 2008

Journal Articles

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Steffen Klippel, Nicholas Mitsiades, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2008) 112 (11): 219.

https://doi.org/10.1182/blood.V112.11.219.219

Published: 2008

Journal Articles

Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs

Jana Jakubikova, Jan Sedlak, Steffen Klippel, Merav Leiba, Yu-Tzu Tai, Teru Hideshima, Klaus Podar, Dharminder Chauhan, Noopur Raje, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2008) 112 (11): 2648.

https://doi.org/10.1182/blood.V112.11.2648.2648

Published: 2008

Journal Articles

In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway.

Steffen Klippel, Jana Jakubikova, Lauren Jenkins, Joseph M. Negri, Yevgenia Tesmenitsky, Melissa Rooney, Jake Delmore, Douglas W. McMillin, R. Selliah, P. Robbins, Nicholas Mitsiades, Robert Schlossman, Sudhir Sahasrabudhe, Kenneth C. Anderson, Paul G. Richardson, Constantine S. Mitsiades

Blood (2007) 110 (11): 540.

https://doi.org/10.1182/blood.V110.11.540.540

Published: 2007

Journal Articles

Compartment-Specific Bioluminescence Imaging (CS-BLI): A High-Throughput Approach To Identify Novel Anti-Neoplastic Therapies That Overcome the Protection of Stromal Cells.

Douglas W. McMillin, Joseph M. Negri, Patrick Hayden, Ellen Weisberg, Steffen Klippel, Robert Schlossman, Nikhil C. Munshi, Nicholas Mitsiades, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2007) 110 (11): 536.

https://doi.org/10.1182/blood.V110.11.536.536

Published: 2007

Journal Articles

Essential Role of Jun Family Transcription Factors in PU.1-Induced Leukemic Stem Cell Transformation.

Ulrich Steidl, MD, PhD, Frank Rosenbauer, PhD, Roel G.W Verhaak, Xuesong Gu, PhD, Hasan H. Otu, PhD, Shakir Kolia, PhD, Bronwyn M. Owens, PhD, Steffen Klippel, PhD, Katharina Wagner, MD, Manuel Aivado, MD, Emmanuelle Passegue, PhD, Towia A. Libermann, PhD, Ruud Delwel, PhD, Daniel G. Tenen, MD

Blood (2005) 106 (11): 463.

https://doi.org/10.1182/blood.V106.11.463.463

Published: 2005

Journal Articles

Neutrophil PRV-1 mRNA Overexpression in Chronic Idiopathic Myelofibrosis May Be Associated with Poor Prognosis.

Heinz Gisslinger, MD, Steffen Klippel, PD, Hermann Heimpel, MD, Mathias Kees, MD, Alexandra Kaider, PD, Juergen Thiele, MD, Heike L. Pahl, PD

Blood (2004) 104 (11): 4762.

https://doi.org/10.1182/blood.V104.11.4762.4762

Published: 2004

Journal Articles

Knockdown of the Transcription Factor PU.1 Causes Characteristic Transcriptional Changes in Hematopoietic Stem Cells Prior to Leukemic Transformation.

Ulrich Steidl, MD PhD, Frank Rosenbauer, PhD, Xuesong Gu, PhD, Bronwyn Owens, PhD, Steffen Klippel, PhD, Katharina Wagner, MD, Manuel Aivado, MD, Towia A. Libermann, PhD, Daniel G. Tenen, MD

Blood (2004) 104 (11): 1112.

https://doi.org/10.1182/blood.V104.11.1112.1112

Published: 2004

Journal Articles

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis

Steffen Klippel, Elisabeth Strunck, Snezana Temerinac, Anthony J. Bench, Gerold Meinhardt, Ursula Mohr, Rosi Leichtle, Anthony R. Green, Martin Griesshammer, Hermann Heimpel, Heike L. Pahl

Blood (2003) 102 (10): 3569–3574.

https://doi.org/10.1182/blood-2003-03-0919

Published: 2003

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions.

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro , and Inhibits Tumor Growth and Improves Survival in in Vivo M ultiple Myeloma(MM) Animal Models

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs

In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway.

Compartment-Specific Bioluminescence Imaging (CS-BLI): A High-Throughput Approach To Identify Novel Anti-Neoplastic Therapies That Overcome the Protection of Stromal Cells.

Essential Role of Jun Family Transcription Factors in PU.1-Induced Leukemic Stem Cell Transformation.

Neutrophil PRV-1 mRNA Overexpression in Chronic Idiopathic Myelofibrosis May Be Associated with Poor Prognosis.

Knockdown of the Transcription Factor PU.1 Causes Characteristic Transcriptional Changes in Hematopoietic Stem Cells Prior to Leukemic Transformation.

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only